share_log

I-Mab (NASDAQ:IMAB) Dips 17% This Week as Increasing Losses Might Not Be Inspiring Confidence Among Its Investors

I-Mab (NASDAQ:IMAB) Dips 17% This Week as Increasing Losses Might Not Be Inspiring Confidence Among Its Investors

I-MAB(納斯達克:IMAB)本週下跌 17%,因為增加的損失可能不會激發投資者的信心
Simply Wall St ·  2023/03/11 21:25

It's not a secret that every investor will make bad investments, from time to time. But serious investors should think long and hard about avoiding extreme losses. It must have been painful to be a I-Mab (NASDAQ:IMAB) shareholder over the last year, since the stock price plummeted 78% in that time. While some investors are willing to stomach this sort of loss, they are usually professionals who spread their bets thinly. Notably, shareholders had a tough run over the longer term, too, with a drop of 73% in the last three years. More recently, the share price has dropped a further 29% in a month.

這不是一個秘密,每個投資者會不時做出不良的投資。但是,嚴肅的投資者應該長時間努力地思考避免極端損失。它一定是痛苦的是 I-生物 (納斯達克:IMAB)股東在過去一年,因為股票價格在那個時候下跌了 78%。雖然一些投資者願意忍受這種損失, 他們通常是專業人士誰散佈他們的賭注薄.值得注意的是,股東在長期內也經歷了艱難的運行,過去三年下降了 73%。最近,股價在一個月內進一步下降了 29%。

Since I-Mab has shed US$63m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由於 I-Mab 在過去 7 天內從其價值中下降了 63 億美元,因此讓我們看看長期下降是否受到企業經濟學的驅動。

Check out our latest analysis for I-Mab

查看我們關於 I-Mab 的最新分析

Because I-Mab made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

由於 I-Mab 在過去十二個月內虧損,我們認為市場可能更關注收入和收入增長,至少就目前而言。無利可圖公司的股東通常預期收入增長強勁。這是因為如果收入增長可以忽略不計,並且永遠不會賺取利潤,那麼公司很難相信一家公司將是可持續的。

I-Mab's revenue didn't grow at all in the last year. In fact, it fell 92%. That looks like a train-wreck result to investors far and wide. If you need more proof of that, check the share price. (Hint: it tanked 78%). Our mindset doesn't have a lot of time for stocks like this. A healthy aversion to bagholding (holding potentially worthless stocks) sees many shareholders avoid buying shares like this, rightly or wrongly.

過去一年,I-Mab 的收入完全沒有增長。實際上,它下降了 92%。對於廣泛的投資者來說,這看起來像是火車殘骸的結果。如果您需要更多證明,請檢查股價。(提示:它坦克了 78%)。我們的心態沒有太多時間來處理這樣的股票。對行袋(持有潛在毫無價值的股票)表示,許多股東都避免購買這樣的股票,無論是正確或錯誤。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下圖描述了隨著時間的推移收入和收入如何變化(通過單擊圖像來顯示確切值)。

earnings-and-revenue-growth
NasdaqGM:IMAB Earnings and Revenue Growth March 11th 2023
納斯達基因指數:IMB 盈利和收入增長 2023 年 3 月 11 日

I-Mab is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. You can see what analysts are predicting for I-Mab in this interactive graph of future profit estimates.

I-Mab 是眾所周知的股票,擁有豐富的分析師報導,這表明對未來增長有所了解。您可以在此查看分析師對 I-MAB 的預測 互動式 未來利潤估計的圖表。

A Different Perspective

不同的角度

The last twelve months weren't great for I-Mab shares, which performed worse than the market, costing holders 78%. Meanwhile, the broader market slid about 8.3%, likely weighing on the stock. Shareholders have lost 20% per year over the last three years, so the share price drop has become steeper, over the last year; a potential symptom of as yet unsolved challenges. We would be wary of buying into a company with unsolved problems, although some investors will buy into struggling stocks if they believe the price is sufficiently attractive. It's always interesting to track share price performance over the longer term. But to understand I-Mab better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with I-Mab , and understanding them should be part of your investment process.

過去十二個月對於 I-MAB 股票來說並不是很好,這種股票的表現比市場差,使持有人成本為 78%。與此同時,更廣泛的市場下滑了約 8.3%,可能會對股票造成重量。在過去三年中,股東每年損失了 20%,因此股價下跌在過去一年中變得更加陡峭,這是尚未解決的挑戰的潛在症狀。我們會警惕購買有未解決問題的公司,儘管如果一些投資者認為價格足夠具有吸引力,則會購買掙扎的股票。跟踪長期的股價表現總是很有趣。但是要更好地理解 I-MAB,我們需要考慮許多其他因素。考慮例如,永遠存在的投資風險幽靈。 我們已經確定了 3 個警告標誌 通過 I-Mab,並了解它們應該是您投資過程的一部分。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然, 通過尋找其他地方,您可能會發現出色的投資。 因此,請先看看這個 自由 我們預計將增加收益的公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

請注意,本文中引用的市場回報反映了當前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?關注內容? 取得聯繫 直接與我們聯繫。 或者,通過電子郵件發送電子郵件給編輯團隊。
這篇文章由簡單牆聖是一般性質. 我們僅使用公正的方法,根據歷史數據和分析師預測提供評論,我們的文章並不打算作為財務建議。 它並不構成購買或出售任何股票的建議,也不會考慮您的目標或您的財務狀況。我們的目標是為您帶來由基本數據驅動的長期集中分析。請注意,我們的分析可能不會考慮最新的價格敏感公司公告或定性材料。簡易華街在提及的任何股票中都沒有倉位。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論